Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration.
Amanda Marie MooreZohra NooruddinKelly R RevelesJim M KoellerJennifer M WhiteheadKathleen FranklinParomita DattaMunaf A AlkadimiLance BrannmanIon CotarlaAndrew J FrankartTiernan J MulrooneyXavier JonesChristopher Raymond FreiPublished in: The oncologist (2023)
Race was not found to be linked with TID, TI, or TD in this real-world study of patients with unresectable stage III NSCLC treated with durvalumab at the VHA.